JP7224917B2 - 組成物 - Google Patents

組成物 Download PDF

Info

Publication number
JP7224917B2
JP7224917B2 JP2018551137A JP2018551137A JP7224917B2 JP 7224917 B2 JP7224917 B2 JP 7224917B2 JP 2018551137 A JP2018551137 A JP 2018551137A JP 2018551137 A JP2018551137 A JP 2018551137A JP 7224917 B2 JP7224917 B2 JP 7224917B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically active
binding polypeptide
active binding
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018551137A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019514855A5 (OSRAM
JP2019514855A (ja
Inventor
クロエ スコット
ウエスト マイク
ロバーツ ケビン
カールトン ティム
マッジョーレ ルアナ
キュービット マリオン
ワール ゲーリー
ワフリクフ ジョン
フロッドシャム マイク
Original Assignee
ソリッソ ファーマシューティカルズ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソリッソ ファーマシューティカルズ，インク． filed Critical ソリッソ ファーマシューティカルズ，インク．
Publication of JP2019514855A publication Critical patent/JP2019514855A/ja
Publication of JP2019514855A5 publication Critical patent/JP2019514855A5/ja
Priority to JP2023017273A priority Critical patent/JP7496906B2/ja
Application granted granted Critical
Publication of JP7224917B2 publication Critical patent/JP7224917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
JP2018551137A 2016-03-31 2017-03-31 組成物 Active JP7224917B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023017273A JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16163178.3 2016-03-31
EP16163178 2016-03-31
PCT/EP2017/057775 WO2017167997A1 (en) 2016-03-31 2017-03-31 Compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023017273A Division JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Publications (3)

Publication Number Publication Date
JP2019514855A JP2019514855A (ja) 2019-06-06
JP2019514855A5 JP2019514855A5 (OSRAM) 2020-05-14
JP7224917B2 true JP7224917B2 (ja) 2023-02-20

Family

ID=55646428

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018551137A Active JP7224917B2 (ja) 2016-03-31 2017-03-31 組成物
JP2023017273A Active JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023017273A Active JP7496906B2 (ja) 2016-03-31 2023-02-08 組成物

Country Status (10)

Country Link
US (2) US10772839B2 (OSRAM)
EP (1) EP3435982A1 (OSRAM)
JP (2) JP7224917B2 (OSRAM)
KR (1) KR102376369B1 (OSRAM)
CN (2) CN109152738B (OSRAM)
AU (2) AU2017240190A1 (OSRAM)
CA (2) CA3019482A1 (OSRAM)
IL (1) IL261792B (OSRAM)
SG (1) SG11201807402PA (OSRAM)
WO (2) WO2017167997A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249144B2 (en) * 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2017012662A (es) 2015-03-31 2018-05-11 Vhsquared Ltd Polipeptidos.
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
JP7224917B2 (ja) 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物
WO2018060453A1 (en) * 2016-09-30 2018-04-05 Vhsquared Limited Compositions
AU2017378393B2 (en) 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
EP3600416B1 (en) * 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
ES2938608T3 (es) * 2017-09-20 2023-04-13 Tillotts Pharma Ag Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020144164A1 (en) 2019-01-07 2020-07-16 Bactolife Aps Pathogen binding proteins
WO2020243393A1 (en) * 2019-05-30 2020-12-03 Vta Labs, Llc Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron's disease and ulcerative colitis
EP3986571A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986570A1 (en) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Compositions
CN114514243B (zh) 2019-06-21 2025-01-24 索瑞索制药公司 多肽
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US20230174554A1 (en) * 2020-05-18 2023-06-08 Shenzhen TargetRx. Inc. Solid form of macrocyclic compound, preparation therefor and use thereof
CN113768051B (zh) * 2020-06-09 2024-03-19 中粮营养健康研究院有限公司 饲料添加剂及其制备方法和其在饲料中的应用以及替抗饲料
GB202017863D0 (en) * 2020-11-12 2020-12-30 Intract Pharma Ltd Novel compositions
WO2024163874A2 (en) * 2023-02-03 2024-08-08 Avexegen Therapeutics, Inc. Stable and controlled release formulations of neuregulin-4 analogs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
JP2010502759A (ja) 2006-09-12 2010-01-28 コスモ・テクノロジーズ・リミテツド タンパク質物質の経口または直腸投与のための医薬組成物
WO2015176031A3 (en) 2014-05-15 2015-12-30 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2010126A (en) 1934-03-19 1935-08-06 Frank L Mclaughlin Measuring and dispensing can
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
EP0725789B1 (en) * 1993-09-20 2003-03-19 Anadis Ltd. Method of obtaining immunoglobulins from colostrum and their use in pharmaceutical composition
CN1116898C (zh) * 2000-02-21 2003-08-06 湖北楚冠实业股份有限公司 一种口服免疫球蛋白制剂及其制备方法
EP1558647B1 (en) 2002-11-08 2015-06-10 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
AP2007004019A0 (en) * 2004-11-25 2007-06-30 Unilever Plc Heavy chain and single domain antibodies
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
US20080026820A1 (en) * 2006-07-05 2008-01-31 Aruze Gaming America, Inc. Slot machine and playing method thereof
AU2007300221A1 (en) 2006-09-25 2008-04-03 Medimmune, Llc. Stabilized antibody formulations and uses thereof
AU2008218595B2 (en) * 2007-02-20 2012-05-24 Allergan Therapeutics LLC Stable digestive enzyme compositions
EP2061440A2 (en) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
WO2009037264A2 (en) 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
HUE038452T2 (hu) 2007-11-13 2018-10-29 Meritage Pharma Inc Gyomor és bélrendszeri gyulladások kezelésére szolgáló kompozíciók
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
CN101964403A (zh) 2009-07-23 2011-02-02 比克国际(天津)有限公司 一种电池组的封装方法及电池组
EP2533814A2 (en) 2010-02-11 2012-12-19 Ablynx N.V. Delivery of immunoglobulin variable domains and constructs thereof
BR112012022223B1 (pt) 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
JP5931757B2 (ja) 2010-03-10 2016-06-08 インキューブ ラブズ， エルエルシー 嚥下可能な薬物送達デバイスを用いた腸管の内腔への送達のための治療薬調製物
US9468679B2 (en) 2011-03-28 2016-10-18 Ablynx N.V. Method for producing solid formulations comprising immunoglobulin single variable domains
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
PL2849723T3 (pl) 2012-05-18 2018-10-31 Genentech, Inc. Formulacje o wysokim stężeniu przeciwciał monoklonalnych
EP2887960A2 (en) * 2012-08-21 2015-07-01 Glaxo Group Limited Compositions comprising a single variable domain and camostat mesylate (cm)
KR20150132332A (ko) 2013-03-15 2015-11-25 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 저농도 항체 제형
US20160228371A1 (en) 2013-10-18 2016-08-11 Abbvie Inc. Stable solid units and methods of making the same
FR3026012B1 (fr) * 2014-09-23 2017-12-01 Soc D'exploitation De Produits Pour Les Industries Chimiques Seppic Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigenique
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
MX2017012662A (es) * 2015-03-31 2018-05-11 Vhsquared Ltd Polipeptidos.
JP7224917B2 (ja) 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502759A (ja) 2006-09-12 2010-01-28 コスモ・テクノロジーズ・リミテツド タンパク質物質の経口または直腸投与のための医薬組成物
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
WO2015176031A3 (en) 2014-05-15 2015-12-30 Incube Labs, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins

Also Published As

Publication number Publication date
JP2023058591A (ja) 2023-04-25
WO2017171535A3 (en) 2017-12-07
KR20190003493A (ko) 2019-01-09
WO2017171535A8 (en) 2017-11-16
US10980748B2 (en) 2021-04-20
CN109152738B (zh) 2023-10-13
IL261792B (en) 2022-06-01
JP7496906B2 (ja) 2024-06-07
CA3053757A1 (en) 2017-10-05
AU2017240190A1 (en) 2018-09-20
EP3435982A1 (en) 2019-02-06
US20190008778A1 (en) 2019-01-10
US10772839B2 (en) 2020-09-15
CA3019482A1 (en) 2017-10-05
KR102376369B1 (ko) 2022-03-18
AU2023200377B2 (en) 2025-04-10
WO2017171535A2 (en) 2017-10-05
IL261792A (en) 2018-10-31
CN109152738A (zh) 2019-01-04
US20200368167A1 (en) 2020-11-26
SG11201807402PA (en) 2018-09-27
CN117243904A (zh) 2023-12-19
JP2019514855A (ja) 2019-06-06
AU2023200377A1 (en) 2023-02-23
WO2017167997A1 (en) 2017-10-05

Similar Documents

Publication Publication Date Title
JP7496906B2 (ja) 組成物
AU2024219328B2 (en) Preparation of solid dosage forms comprising antibodies by solution/suspension layering
US20240000714A1 (en) Topical treatment of inflammatory bowel disease using antibodies and fragments thereof
JP2019514855A5 (OSRAM)
JP7316268B2 (ja) 湿式造粒、押出および球形化による抗体を含む固形剤形の調製方法
HK40104085A (zh) 组合物
CN120981225A (zh) 用于在下部胃肠道中缓释的包含抗体的固体口服剂型
HK40024511A (en) Preparation of solid dosage forms comprising antibodies by solution/suspension layering
HK40005745A (en) Preparation of solid dosage forms comprising antibodies by solution/suspension layering
HK1262364A1 (en) Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
HK40005745B (en) Preparation of solid dosage forms comprising antibodies by solution/suspension layering
EA044207B1 (ru) Получение твердых лекарственных форм, содержащих антитела, путем наслаивания раствора суспензии

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211111

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230208

R150 Certificate of patent or registration of utility model

Ref document number: 7224917

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150